<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274755</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000441015</org_study_id>
    <secondary_id>UCSF-05106</secondary_id>
    <nct_id>NCT00274755</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas</brief_title>
  <official_title>Improved Characterization of Brain Tumors By MRI and MRS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and magnetic&#xD;
      resonance spectroscopic imaging (MRSI), (done before, during, and after treatment) may help&#xD;
      doctors predict a patient's response to treatment and help plan the best treatment.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well MRI and MRSI evaluate patients who are&#xD;
      undergoing treatment for gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the magnetic resonance spectroscopic imaging (MRSI) characteristics of&#xD;
           patients who are undergoing treatment for supratentorial glioma.&#xD;
&#xD;
        -  Determine the survival of patients who undergo magnetic resonance imaging and MRSI.&#xD;
&#xD;
        -  Determine the clinical outcome of patients who undergo these imaging procedures.&#xD;
&#xD;
        -  Correlate measures of metabolic tumor burden (i.e., CNI, CCCrI, CrNI, and LLI) with&#xD;
           survival and clinical outcome in patients who undergo these imaging procedures.&#xD;
&#xD;
        -  Determine the time to clinical progression in patients who undergo these imaging&#xD;
           procedures.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 treatment groups based on grade of disease.&#xD;
&#xD;
        -  Group 1 (patients with grade II glioma): Patients undergo magnetic resonance imaging&#xD;
           (MRI) and magnetic resonance spectroscopic imaging (MRSI). Patients then receive&#xD;
           chemotherapy. Patients undergo repeat MRI/MRSI after courses 2 and 4 of chemotherapy.&#xD;
&#xD;
        -  Group 2 (patients with grade III-IV glioma): Patients undergo MRI/MRSI and then undergo&#xD;
           surgical resection of the tumor. Patients then receive chemoradiotherapy. Patients&#xD;
           undergo repeat MRI/MRSI within 2 weeks and at 2 months after completion of radiotherapy.&#xD;
&#xD;
      Patients are followed for recurrence, disease progression, and survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 250 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to clinical progression</measure>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance spectroscopic imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed supratentorial glioma&#xD;
&#xD;
               -  Grade II-IV disease&#xD;
&#xD;
               -  Previously untreated disease&#xD;
&#xD;
          -  Eligible for surgical resection and/or chemotherapy with or without radiotherapy&#xD;
&#xD;
          -  Tumor accessible by magnetic resonance spectroscopic imaging&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy â‰¥ 8 weeks&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No contraindication for magnetic resonance examinations, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Cardiac pacemaker or fibrillator&#xD;
&#xD;
               -  Aneurysm clip&#xD;
&#xD;
               -  Insulin or infusion pump&#xD;
&#xD;
               -  Any implant held in place by a magnet&#xD;
&#xD;
               -  Metal contamination anywhere in the body&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No prior treatment for the malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah J. Nelson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2006</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

